Chronic hand eczema (CHE) is a prevalent skin condition, affecting approximately 5.6% of adults worldwide. The burden of CHE extends beyond its physical symptoms, impacting various aspects of daily life.
Research suggests that 4.7% of adults have physician-diagnosed CHE. Notably, CHE can be occupationally related, with 21.5% of individuals attributing their condition to their job and 30.3% to household or leisure activities.
Despite treatment, CHE symptoms often persist. Studies show that the majority of CHE patients receive topical corticosteroids, with varying potencies. However, a significant proportion (27.4%) escalate to alternative therapies, including phototherapy, systemic immunosuppressants, and biologics.
The persistence of symptoms despite treatment indicates an unmet need in CHE management. Further research is required to identify effective and accessible treatment options that can alleviate the burden of this debilitating condition.
Large-scale studies like CHECK provide valuable insights into the prevalence, impact, and treatment patterns of CHE. By understanding the scope of this condition, healthcare providers and researchers can develop more effective interventions and support mechanisms for those affected by it.
